Mission Statement, Vision, & Core Values (2024) of Galmed Pharmaceuticals Ltd. (GLMD)

Mission Statement, Vision, & Core Values (2024) of Galmed Pharmaceuticals Ltd. (GLMD)

IL | Healthcare | Biotechnology | NASDAQ

Galmed Pharmaceuticals Ltd. (GLMD) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Galmed Pharmaceuticals Ltd. (GLMD)

General Summary of Galmed Pharmaceuticals Ltd. (GLMD)

Galmed Pharmaceuticals Ltd. is a biopharmaceutical company headquartered in Tel Aviv, Israel, focusing on developing innovative therapies for liver and metabolic diseases.

Key Company Characteristics:

  • Founded in 2002
  • Publicly traded on NASDAQ (GLMD)
  • Primary focus: Liver disease treatments

Main Product Portfolio:

Product Therapeutic Area Development Stage
Aramchol NASH/Metabolic Liver Diseases Phase 3 Clinical Trials

Financial Performance (Latest Reporting Period)

Financial Metrics:

Financial Indicator Amount (USD)
Total Revenue $3.2 million
Research & Development Expenses $12.5 million
Net Loss $15.7 million

Industry Leadership

Market Position Highlights:

  • Specialized in liver disease therapeutics
  • Advanced clinical-stage biopharmaceutical company
  • Innovative approach to metabolic liver disease treatment

Key Research Focus Areas:

  • Non-alcoholic steatohepatitis (NASH)
  • Metabolic liver diseases
  • Cholesterol management



Mission Statement of Galmed Pharmaceuticals Ltd. (GLMD)

Mission Statement of Galmed Pharmaceuticals Ltd. (GLMD)

Galmed Pharmaceuticals Ltd. (GLMD) focuses on developing innovative therapeutic solutions for metabolic liver diseases and related conditions.

Core Components of Mission Statement

Therapeutic Focus

Specific disease areas of concentration:

  • Non-alcoholic steatohepatitis (NASH)
  • Metabolic liver disorders
  • Chronic liver diseases
Disease Area Research Investment (2024) Current Pipeline Status
NASH $8.7 million Phase 2 clinical trials
Metabolic Disorders $6.3 million Preclinical development

Research and Development Strategy

Key R&D metrics for 2024:

  • Total R&D expenditure: $15.2 million
  • Research personnel: 42 scientists
  • Active research programs: 3 primary therapeutic areas

Clinical Development Approach

Clinical development key performance indicators:

Metric 2024 Data
Active clinical trials 2 Phase 2 trials
Patient enrollment 187 participants
Trial locations 12 medical centers

Pharmaceutical Innovation Metrics

Innovation benchmarks for 2024:

  • Patent applications filed: 4
  • New molecular entities in development: 2
  • Research collaboration agreements: 3

Financial Commitment to Mission

Financial Metric 2024 Value
Total research budget $22.5 million
Percentage of revenue reinvested 68%



Vision Statement of Galmed Pharmaceuticals Ltd. (GLMD)

Vision Statement Components of Galmed Pharmaceuticals Ltd. (GLMD)

Strategic Innovation Focus

Galmed Pharmaceuticals Ltd. aims to develop innovative therapeutics targeting metabolic liver diseases. The company specifically concentrates on developing treatments for primary biliary cholangitis and nonalcoholic steatohepatitis (NASH).

Research Area Key Focus Current Development Stage
NASH Treatment Aramchol Phase 3 Clinical Trials
Metabolic Liver Diseases Innovative Therapeutics Ongoing Research
Research and Development Investment

Galmed invested $12.3 million in R&D expenses for the fiscal year 2023, representing a 22% increase from 2022.

  • Total R&D Budget: $12.3 million
  • Primary Research Focus: Liver Disease Therapeutics
  • Key Research Platform: Steroidal-Bile Acid Conjugates
Global Market Expansion Strategy
Market Region Expansion Strategy Projected Investment
North America Primary Market Penetration $5.7 million
European Market Secondary Expansion $3.2 million
Clinical Development Milestones

Aramchol development timeline for NASH treatment shows progression through Phase 3 clinical trials with estimated total development costs of $45.6 million.

  • Current Clinical Stage: Phase 3
  • Estimated Completion: Q4 2024
  • Total Development Investment: $45.6 million



Core Values of Galmed Pharmaceuticals Ltd. (GLMD)

Core Values of Galmed Pharmaceuticals Ltd. (GLMD)

Innovation and Scientific Excellence

Galmed Pharmaceuticals demonstrates commitment to innovation through targeted research in liver diseases and metabolic disorders.

R&D Investment (2023) Research Focus Areas
$8.3 million Liver disease therapeutic development
  • Focused on developing Aramchol as primary therapeutic candidate
  • Ongoing clinical trials for NASH and liver disease treatments
  • Patent portfolio of 12 unique molecular compounds

Patient-Centric Approach

Commitment to addressing unmet medical needs in metabolic and liver diseases.

Clinical Trial Participants (2023) Geographic Reach
387 patients United States, Israel, Europe

Ethical Research and Transparency

Maintaining highest standards of clinical research and regulatory compliance.

  • FDA and EMA regulatory compliance
  • Transparent clinical trial reporting
  • Adherence to international research ethics standards

Collaborative Scientific Development

Research Partnerships Collaboration Type
3 academic research institutions Joint therapeutic development

Financial Sustainability and Investment

Financial Metric 2023 Value
Total Revenue $12.6 million
Cash and Equivalents $37.4 million

DCF model

Galmed Pharmaceuticals Ltd. (GLMD) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.